Last reviewed · How we verify
NCT07131371: SMASH-HCM
Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions
trial in HCM - Hypertrophic Cardiomyopathy in 2,500 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | Tampere University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 2,500 |
| Start date | 15 January 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Finland |
Conditions studied
- HCM - Hypertrophic Cardiomyopathy — all drugs for HCM - Hypertrophic Cardiomyopathy →
Sponsor
Tampere University
Who can join
18 and older, any sex, with HCM - Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of SMASH-HCM is to develop a digital twin or virtual model of the heart and vascular system with sympathetic nerve control that integrates multi-scale and multi-organ spatiotemporal biophysical data from a multitude of sources. SMASH-HCM's digital twin powered platform will dramatically improve hypertrophic cardiomyopathy (HCM) patient stratification and disease management through stepwise deep phenotyping integrated in clinical and patient-guided workflows.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07131371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HCM - Hypertrophic Cardiomyopathy
Currently open trials in the same condition.
- NCT07372196 — Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy · NA · recruiting
- NCT07340762 — Automated Reports Generation of Cardiovascular Magnetic Resonance Imaging · active not recruiting
- NCT07382128 — Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes · recruiting
- NCT06947590 — Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy · NA · active not recruiting
- NCT06604169 — An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopat · active not recruiting
Other Tampere University trials
Trials by the same sponsor.
- NCT05786001 — Multimodal Noninvasive Assessment of Peripheral Circulation in Chronic Limb-threatening Ischemia · recruiting
- NCT06322511 — Dialogical Family Guidance PostDoc Study · NA · recruiting
- NCT05766202 — The MOTIVE (Multiparas Overcoming Childbirth Fear Through Intervention and Empowerement) Feasibility Trial · NA · completed
- NCT05626543 — The Effect of Mindfulness-based Cognitive Behavior Therapy on Occupational Stress Management · NA · completed
- NCT04424511 — Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07131371 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tampere University
- Last refreshed: 27 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07131371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing